Krka d.d.

Krka reports H1 2026 sales growth of 6.7% to €1,113.8 million and an EBITDA margin of 31.9% (H1 2025: 28.9%). EBIT rose 20% to €309 million with a margin of 27.6%, and net profit climbed to €260 million (+5%). Five of six regions recorded growth; Eastern Europe remains the largest region with €405.2 million (+9%). The company confirms its 2026 targets: around €2,144 million in sales and a net profit of approximately €405 million. » Altro su de.investing.com

Krka reports record revenue of €566 million in Q1 2026 (+8%) and an operating profit of €152 million (+24%), with an EBITDA margin of 31%—one of the highest levels in the company’s history. Net profit fell to €121 million (−21% versus Q1 2025) due to a strong year‑ago comparison. Management highlights growth from product-portfolio expansion, strong cash flows and a proposed quarterly dividend of €9.1 per share; risks remain currency fluctuations, supply-chain issues and competitive pressure. » Altro su de.investing.com

The Krka Group reported 2026 revenue of €2.041 billion, up 7% year-on-year, marking the first time in the company’s history it exceeded €2 billion. Net profit rose 13% to €401 million, EBITDA was €560 million (EBITDA margin 27.4%). In 2025 Krka launched seventeen new products, is focusing on chronic diseases and expanding in heart failure and obesity, and plans joint ventures in China and India. For 2026 the company forecasts revenue of €2.144 billion and plans to invest €140 million; the share price reacted with a 1.04% increase. » Altro su de.investing.com